{
    "Trade/Device Name(s)": [
        "Rightest Blood Glucose Monitoring System Max",
        "Rightest Blood Glucose Monitoring System Max Plus",
        "GE Blood Glucose Monitoring System Max",
        "GE Blood Glucose Monitoring System Max Plus"
    ],
    "Submitter Information": "Bionime Corporation",
    "510(k) Number": "K173638",
    "Predicate Device Reference 510(k) Number(s)": [
        "K140210"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "August 17, 2018",
    "Summary Letter Received Date": "July 20, 2018",
    "Submission Date": "June 15, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Rightest Meter Max",
        "Rightest Meter Max Plus",
        "GE Meter Max",
        "GE Meter Max Plus"
    ],
    "Method(s)/Technology(ies)": [
        "Dehydrogenase electrochemical sensor"
    ],
    "Methodologies": [
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "Instrument",
        "System",
        "Reagent",
        "Consumable",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Rightest and GE Blood Glucose Monitoring Systems Max/Max Plus for quantitative measurement of glucose in capillary whole blood using dehydrogenase electrochemical sensor.",
    "Indications for Use Summary": "Intended for self-testing by individuals with diabetes at home for quantitative measurement of glucose in fresh capillary whole blood from fingertips, forearm, or palm as an aid to monitor diabetes control; not for diagnosis or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}